MRNA stock surged 8% on Oct 5, 2026 as Moderna nears a full melanoma readout, and the company was confirmed for Nasdaq-100 inclusion effective December 2025 replacing Warner Bros Discovery. The dual catalysts drove real-time buying interest in mrna stock.
💡 Frequently Asked Questions (FAQ)
- Q: Why did mrna stock surge 8% on Oct 5, 2026?
- A: The rally was driven by two catalysts: Moderna nearing a full melanoma readout and confirmation of Nasdaq-100 inclusion effective December 2025 replacing Warner Bros Discovery.
- Q: Is Moderna being added to the Nasdaq-100?
- A: Yes, Moderna was confirmed for Nasdaq-100 inclusion effective December 2025, which typically increases passive fund buying and visibility.
- Q: What is the melanoma catalyst for MRNA stock?
- A: Moderna is approaching a full melanoma data readout, and positive results could validate its mRNA oncology pipeline and boost investor sentiment.